{"product_id":"kyxata-carboplatin-10-mg-intravenous-chemotherapy-multiple-dose-vial-8-ml-rx0","title":"Kyxata Carboplatin 10 mg Intravenous Chemotherapy Multiple-Dose Vial 8 mL (Rx)","description":"\u003ch1\u003eKyxata (Carboplatin) 10 mg\/mL Injection\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cem\u003eKyxata\u003c\/em\u003e is a brand of \u003cstrong\u003ecarboplatin injection\u003c\/strong\u003e, a platinum-based chemotherapy drug. It comes as a sterile pale-yellow solution where each milliliter (mL) contains 10 mg of carboplatin. (Vial strengths include 20 mg\/2 mL, 80 mg\/8 mL, and 500 mg\/50 mL, all at 10 mg\/mL.) Carboplatin works by binding DNA and forming cross-links, blocking DNA replication and causing cancer cell death.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eUses (Indications)\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdvanced ovarian cancer (first-line):\u003c\/strong\u003e Kyxata is used \u003cstrong\u003ewith other chemotherapy agents\u003c\/strong\u003e (e.g. cyclophosphamide) as initial treatment for advanced ovarian carcinoma in adults.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecurrent ovarian cancer:\u003c\/strong\u003e It is also indicated as a \u003cstrong\u003esingle agent\u003c\/strong\u003e for ovarian carcinoma that has recurred after prior chemotherapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eDosage and Administration\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration:\u003c\/strong\u003e Given only by intravenous infusion (usually by an oncologist or in a cancer clinic). It is \u003cstrong\u003enot\u003c\/strong\u003e a self-administered drug.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDose calculation:\u003c\/strong\u003e Dosing is based on body size and kidney function. Doctors often use the Calvert formula: \u003cem\u003eDose (mg) = Target AUC (area under curve) × (GFR + 25)\u003c\/em\u003e, where GFR (glomerular filtration rate) is estimated from creatinine clearance. This ensures the dose is adjusted for each patient’s renal function.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical dosing:\u003c\/strong\u003e For example, an initial regimen might be \u003cstrong\u003e300 mg\/m²\u003c\/strong\u003e (or targeting an AUC of 4–6 mg·min\/mL) on Day 1, combined with cyclophosphamide, every 4 weeks (for up to 6 cycles). For recurrent disease as a single agent, around \u003cstrong\u003e360 mg\/m²\u003c\/strong\u003e (or AUC 4–6) on Day 1 every 4 weeks is common. Exact doses will be determined by the treating oncologist.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonitoring:\u003c\/strong\u003e Complete blood counts are checked before each cycle because carboplatin can severely lower blood cell levels. Anti-nausea medications are usually given before the infusion to prevent vomiting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSide Effects and Precautions\u003c\/h2\u003e\n\u003cp\u003eKyxata has serious potential side effects, as with most chemotherapy agents. Key points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMyelosuppression (low blood counts):\u003c\/strong\u003e The most important toxicity is \u003cem\u003ebone marrow suppression\u003c\/em\u003e. This drug commonly causes neutropenia (low white cells), thrombocytopenia (low platelets), and anemia. This can lead to severe infections, bleeding, or fatigue. Doctors monitor blood counts closely and may delay or reduce doses if counts are too low.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNausea and vomiting:\u003c\/strong\u003e These are common. Patients are typically given antiemetics (anti-vomiting drugs) before and after treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAllergic reactions:\u003c\/strong\u003e Kyxata can cause \u003cem\u003esevere hypersensitivity\u003c\/em\u003e, including anaphylactic reactions, sometimes within minutes of starting the infusion. Medical staff will watch for any rash, difficulty breathing, or other allergic signs during administration. If a serious reaction occurs, the infusion is stopped immediately and managed appropriately.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePeripheral neuropathy:\u003c\/strong\u003e Tingling, numbness, or weakness in the hands or feet can occur. Dose adjustments may be needed if neuropathy develops.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOther common effects:\u003c\/strong\u003e Hair loss (alopecia) and fatigue are very common. Other frequent side effects include nausea, anemia, low platelet count, and low magnesium or sodium levels.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy and fertility:\u003c\/strong\u003e Carboplatin can cause fetal harm. Women of childbearing potential must use effective contraception and avoid pregnancy during treatment. Men should also use contraception. Breastfeeding is not recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDrug interactions:\u003c\/strong\u003e Avoid concurrent use of certain drugs, especially \u003cstrong\u003eaminoglycoside antibiotics\u003c\/strong\u003e (e.g. gentamicin). Using these together with carboplatin can increase the risk of kidney damage or hearing loss. Your doctor or pharmacist will check all medications to prevent harmful interactions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eImportant Information\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMedical super­vision required:\u003c\/strong\u003e Kyxata is a prescription medication administered only under a doctor’s care. Do \u003cem\u003enot\u003c\/em\u003e attempt to use it on your own.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonitoring:\u003c\/strong\u003e Frequent lab tests (blood counts, kidney function, electrolytes) are needed before and during treatment. The doctor will adjust dosing or delay cycles based on these results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsult professionals:\u003c\/strong\u003e This summary is for general information. Individual dosing and safety measures depend on a patient’s health status and should be managed by oncologists or pharmacists. For full prescribing details, healthcare providers can refer to official sources (e.g. FDA’s Daily Med listing for Kyxata).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eDisclaimer:\u003c\/em\u003e This information is not medical advice. For personal medical concerns or before starting any medication, please consult a licensed healthcare professional.\u003c\/p\u003e","brand":"Mountainside Medical","offers":[{"title":"Default Title","offer_id":53827933962608,"sku":"83831-0141-08","price":625.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Kyxata-Carboplatin-10-mg-Intravenous-Chemotherapy.jpg?v=1779375414","url":"https:\/\/www.mountainside-medical.com\/products\/kyxata-carboplatin-10-mg-intravenous-chemotherapy-multiple-dose-vial-8-ml-rx0","provider":"Mountainside Medical","version":"1.0","type":"link"}